2-(N-棕榈酰氨基)-4-硝基苯基beta-D-吡喃葡萄糖苷 | 61443-58-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-(N-棕榈酰氨基)-4-硝基苯基beta-D-吡喃葡萄糖苷
• 英文名称: N-[2-(beta-D-glucopyranosyloxy)-5-nitrophenyl]palmitamide
• 英文别名: N-[5-nitro-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]hexadecanamide
• CAS: 61443-58-1
• 化学式: C28H46N2O9
• 分子量: 554.7
• InChiKey: VQANZNCUHNPTGV-TWHDSSIESA-N

物化性质

• 沸点：
  738.2±60.0 °C(Predicted)
• 密度：
  1.225±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  39
• 可旋转键数：
  18
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  174
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• Ligands that enhance endogenous compounds
  申请人：Domantis Limited

  公开号：EP2420251A2

  公开（公告）日：2012-02-22

  The invention relates to ligands that comprise a moiety (e.g., a dAb) that has a binding site with binding specificity for an endogenous target compound but do not substantially inhibit the activity of said endogenous target compound. Preferably, the ligand does not bind to the active site of an endogenous target compound. The invention relates to the use of such a ligand for the manufacture of a medicament for increasing the half-life, bioavailability, activity or amount of an endogenous target compound to which the ligand binds.

  本发明涉及的配体包含一个分子（如 dAb），该分子具有与内源性靶向化合物结合的特异性结合位点，但不会对所述内源性靶向化合物的活性产生实质性抑制作用。配体最好不与内源性靶向化合物的活性位点结合。本发明涉及使用这种配体制造药物，以提高与配体结合的内源性靶向化合物的半衰期、生物利用度、活性或用量。
• IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS
  申请人：Epipharm Allergie-Service Gesellschaft mbh

  公开号：EP0439585A1

  公开（公告）日：1991-08-07
• LIGANDS THAT ENHANCE ENDOGENOUS COMPOUNDS
  申请人：Domantis Limited

  公开号：EP1814584A2

  公开（公告）日：2007-08-08
• USE OF SUBSTRATES AS PHARMACOLOGICAL CHAPERONES
  申请人：Amicus Therapeutics, Inc.

  公开号：EP2137204A1

  公开（公告）日：2009-12-30
• Ligands That Enhance Endogenous Compounds
  申请人：Tomlinson M. Ian

  公开号：US20070298041A1

  公开（公告）日：2007-12-27

  The invention relates to ligands that comprise a moiety (e.g., a dAb) that has a binding site with binding specificity for an endogenous target compound but do not substantially inhibit the activity of said endogenous target compound. Preferably, the ligand does not bind to the active site of an endogenous target compound. The invention relates to the use of such a ligand for the manufacture of a medicament for increasing the half-life, bioavailability, activity or amount of an endogenous target compound to which the ligand binds.